Vermillion (VRML) continues its wild ride upward from the November low of $4.53 on heavy volume of 546K shares with no apparent news. Two analysts cover the stock with a buy/outperform and Revenue Forecasts in the $7M range for Year Ending Dec.’11 and a Price Target of 10. The market cap is $93M. The stock price high for the year is 34. Vermillion is pure play diagnostic Company focused on unique biomarkers and recently has an approved test OVA1 a test for Ovarian cancer.

Novel Diagnostic Tests Utilizing Biomarkers Working Well for Vermillion – Seeking Alpha

%d bloggers like this: